Contact us

HAYA Therapeutics raises CHF 18 million

Swiss precision medicine biotech Haya Therapeutics is coming out of stealth mode with CHF 18 million in seed funding to boost its anti-fibrotic therapies. The underlying science was initially conducted by Dr. Samir Ounzain and Professor Thierry Pedrazzini of Experimental Cardiology Unit at CHUV and published in top scientific journals. The project won support by […]

Swiss precision medicine biotech Haya Therapeutics is coming out of stealth mode with CHF 18 million in seed funding to boost its anti-fibrotic therapies.

The underlying science was initially conducted by Dr. Samir Ounzain and Professor Thierry Pedrazzini of Experimental Cardiology Unit at CHUV and published in top scientific journals.

The project won support by an InnoTREK grant from the PACTT who protected the lead target sequence WISPER and several additional long non-coding RNAs that were licensed to Haya Therapeutics.
We are thrilled the team is now set to develop the technology to provide promising novel treatment options for patients.

Well done to all the team!

Table of Contents

Interested in this project? Let’s Talk

Get in touch to discuss licensing opportunities, collaborative research, or technical specifications.

Contact Us

Other news & events

All news
Uncategorized
InnoTREK: one-year financial support to create your start-up

You are a UNIL-CHUV researcher who would like to create a start-up and need a financial support to start? Apply for a one-year InnoTREK grant of CHF 100’000.- to launch your project! Applications for the InnoTREK grant can be submitted throughout the year to the Knowledge Transfer UNIL CHUV. Project selection will take place in […]

Uncategorized
BioInnovation Day 2026 : Journée dédiée aux Innovateurs & Investisseurs

  Le BIND BioInnovation Day 2026 aura lieu le 1er avril 2026 au CHUV – Auditoire César Roux. Une trentaine de projets innovants issus des meilleures institutions académiques et de recherche de Suisse occidentale y seront présentés devant le public et les investisseurs. L’événement est organisé par BioAlps en partenariat avec KT UNIL–CHUV et UNITEC. […]

Uncategorized
A Unil Discovery for Vaccine Development Turns into a Start-Up

The CRISPRi-seq technology, stemming from fundamental research within the team of Professor Jan-Willem Veening at the University of Lausanne, has reached a decisive milestone: it has been licensed to the start-up “i-Seq Biotechnology”. This innovation paves the way for new vaccines against diseases for which there is currently no protection. It all started with a […]

What is your situation ?

Our team is available to discuss your needs, for free.

For Researcher

A personalized service to inventors
In collaboration with a professional network, with regards to all aspects of technology evaluation, protection of intellectual property rights and creation of a start-up.
Learn more

For Industry

Find a collaboration, or invest in a technology
We are the primary contact point to engage in any collaboration, partnership or venture with researchers from the University of Lausanne or the CHUV.
Learn more